

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Cotton et al.
Serial No. : 10/672,936
Filed : September 25, 2003
For : NOVEL FORMS OF S-OMEPRAZOLE
Examiner : Aulakh, Charanjit
Group Art Unit : 1625

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8
I hereby certify that this paper is being deposited with the
United States Postal Service as first class mail on the date
indicated below in an envelope addressed to:
Commissioner for Patents, P. O. Box 1450,
Alexandria, VA 22313-1450.

John M. Genova 32,224
Attorney Name PTO Reg. No.

John M Genova 19 May 2006
Signature Date of Signature

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. §1.97(c))**

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the documents cited on the attached Form PTO/SB/08A is respectfully requested.

By an Information Disclosure Statement ("IDS") filed January 9, 2006 in the referenced application, Applicants made of record two pre-grant oppositions recently filed in India against Indian Patent Application Number 1344/DEL/98 (the "Indian patent application"). The Indian

05/23/2006 JBALINAN 00000048 231703 10672936

01 FC:1806 180.00 DA

patent application and the referenced U.S. application, including the grandparent US 6,369,085 (the "085 patent") and parent US 6,677,455 (the "455 patent"), belong to the same patent family and are owned by the same corporate assignee, i.e., AstraZeneca AB.

By this IDS, Applicants wish to make of record the reply or statement, on behalf of the corporate assignee AstraZeneca AB, to each of the two Indian pre-grant oppositions. The exhibits to the replies or statements include:

Exhibit A: a copy of the decision by the Supreme Court of Judicature, the House of Lords, in the UK in the case of *Synthon B.V. v. Smithkline Beecham*;

Exhibit B: a copy of the Declaration under 37 C.F.R. §1.132 of record in the '085 patent;

Exhibit C: a copy of an experimental report submitted of record in EP 0 984 957 which is the European member of the same patent family to which the referenced application and the '085 and '455 patents belong; and

Exhibit D: a copy of a change of corporate name from Astra Aktiebolag to AstraZeneca AB filed with the Indian Patent Office.

The attached Form PTO/SB/08A identifies the two replies or statements.

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(b) but before the mailing date of either: (1) a final action under §1.113 or (2) a notice of allowance under §1.311, whichever occurs first. Authorization is hereby given to charge Deposit Account No. 23-1703 in the amount of One Hundred and Eighty Dollars (\$180.00) to cover the fee as required by 37 C.F.R. §1.17(p) and any other fee that may be required in connection with this communication.

Dated: 19 May 2006

Respectfully submitted,



John M. Genova

Reg. No. 32,224

Customer No. 007470

Attorney Direct Dial: (212) 819-8832

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

1

Complete if Known

Application Number	10/672,936
Filing Date	September 25, 2003
First Named Inventor	Hanna Cotton
Art Unit	1625
Examiner Name	Charanjit Aulakh
Attorney Docket Number	1103329-0502 CON

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Statement with Exhibits A-C on Behalf of the Applicant, AstraZeneca AB, to the Opposition filed by Ranbaxy Laboratories Limited against Indian Patent Application Number 1344/DEL/98	
		Statement with Exhibits A-D on Behalf of the Applicant, AstraZeneca AB, to the Opposition filed by Torrent Pharmaceuticals Limited against Indian Patent Application Number 1344/DEL/98	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.